SCHEMBL1033082

SCHEMBL1033082

C[C@@H](F)C=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623292 1.00
SCHEMBL1030843 1.00
SCHEMBL1028572 0.72
SCHEMBL1028075 0.72
SCHEMBL6663608 0.72
SCHEMBL19508366 0.72
Isobutyraldehyde SCHEMBL2635854 0.70 ADH1B (0.38)
SCHEMBL74788 0.70
Isobutyraldehyde SCHEMBL2996 0.70
Isobutyraldehyde SCHEMBL788159 0.70 ADH1B (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016016446-A1 PROCESS FOR PREPARING 2-FLUOROPROPIONALDEHYDE SANDOZ AG (CH) 2016-02-04 WO claimed
WO-2016016446-A1 PROCESS FOR PREPARING 2-FLUOROPROPIONALDEHYDE SANDOZ AG (CH) 2016-02-04 WO disclosed
WO-2016016446-A1 PROCESS FOR PREPARING 2-FLUOROPROPIONALDEHYDE SANDOZ AG (CH) 2016-02-04 WO disclosed
CN-103073460-B Be applicable to treat the aromatic substance that the arylsulfonyl ylmethyl of the disease responded for the adjustment of dopamine D 3 receptor or aryl sulfonic acid amides replace AbbVie Deutschland GmbH & Co. KG (DE) 2015-09-09 CN disclosed
US-8969552-B2 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor AbbVie Deutschland GmbH & Co. KG (DE) 2015-03-03 US disclosed
EP-2439203-B1 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor ABBVIE DEUTSCHLAND (DE) 2014-11-19 EP disclosed
EP-1812416-B1 ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2013-08-21 EP disclosed
US-8486984-B2 Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor ABBOTT GMBH & CO., KG (DE) 2013-07-16 US disclosed
CN-103073460-A Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor ABBOTT GMBH & CO KG 2013-05-01 CN disclosed
US-8383641-B2 Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor ABBOTT GMBH & CO. KG (DE) 2013-02-26 US disclosed
US-20090143383-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2009-06-04 US disclosed
CN-101421243-A Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor ABBOTT GMBH & CO KG (DE) 2009-04-29 CN disclosed
US-20090048326-A1 Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-02-19 US disclosed
US-20090012074-A1 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-01-08 US disclosed
US-20080318996-A1 6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor ABBOTT GMBH & CO.KG A CORPORATION 2008-12-25 US disclosed
US-20080125589-A1 Process for Production of Fluoro Derivative CENTRAL GLASS COMPANY, LIMITED (JP) 2008-05-29 US disclosed
US-20080096934-A1 Aminoethylaromatic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor ABBOTT GMBH & CO. KG (DE) 2008-04-24 US disclosed
CN-101068801-A Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for the treatment of disorders which respond to modulation of the dopamine D3 receptor ABBOTT GMBH & CO KG (DE) 2007-11-07 CN disclosed
CN-101039900-A 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor ABBOTT GMBH & CO KG (DE) 2007-09-19 CN disclosed
EP-1780194-A1 PROCES FOR PRODUCTION OF OPTICALLY ALPHA-FLUORO-CARBOXYLIC ESTER DERIVATIVES Central Glass Company, Limited (JP) 2007-05-02 EP disclosed